难治性抑郁在家族内的易感性研究
结果显示TRD患者一级亲属发生TRD的调整相对风险(aRR)为9.16(95%CI 7.21-11.63),且精神分裂症、双相障碍、重性抑郁、注意缺陷多动障碍、孤独症谱系障碍、焦虑障碍和强迫症风险均升高,自杀死亡率亦增加。
要点
- TRD患者一级亲属发生TRD的风险显著升高(aRR 9.16,95%CI 7.21-11.63)。
- 一级亲属共聚集多种重性精神障碍风险,包括精神分裂症(aRR 2.36)和双相障碍(aRR 3.74)。
- 有TRD家族史者自杀死亡率增加,宜更早考虑强化治疗而非单药抗抑郁治疗。
核心结论
- TRD表型存在家族传递,并与其他重性精神障碍共聚集,有TRD家族史者自杀死亡风险升高且倾向抗抑郁治疗抵抗。
研究设计与样本
- TRD定义为当前发作中至少经历3种不同抗抑郁治疗且每种剂量与疗程充分,依据处方记录判定。
- 采用改良Poisson回归计算调整相对风险(aRR)及95%CI,分析TRD、其他重性精神障碍和不同死因死亡风险。
主要发现
- TRD患者一级亲属发生TRD的aRR为9.16(95%CI 7.21-11.63)。
- 一级亲属发生精神分裂症aRR 2.36(95%CI 2.10-2.65),双相障碍aRR 3.74(95%CI 3.39-4.13)。
- 一级亲属发生重性抑郁障碍aRR 3.65(95%CI 3.44-3.87),注意缺陷多动障碍aRR 2.38(95%CI 2.20-2.58)。
- 一级亲属发生孤独症谱系障碍aRR 2.26(95%CI 1.86-2.74),焦虑障碍aRR 2.71(95%CI 2.59-2.84),强迫症aRR 3.14(95%CI 2.70-3.66)。
- TRD患者一级亲属收入较低、躯体共病更多且自杀死亡率更高;敏感性和亚组分析验证结果稳健。
关键数值与推荐
- TRD判定标准:当前发作中至少3种不同抗抑郁治疗,每种剂量与疗程充分。
- 有TRD家族史者抗抑郁治疗抵抗倾向增加且自杀死亡风险升高,可考虑更早采用强化治疗而非抗抑郁单药治疗。
临床怎么用
- 对抑郁患者应详细采集TRD家族史,评估其抗抑郁治疗抵抗和自杀风险。
- 有TRD家族史者宜更早考虑强化治疗策略,而非仅用抗抑郁单药治疗。
- 对TRD患者一级亲属应关注其他重性精神障碍的共聚集风险并加强筛查。
局限性
- TRD定义基于处方记录,可能无法完全反映实际服药依从性和治疗充分性。
- 研究基于台湾保险数据库,结论外推至其他人群需谨慎。
- 家族聚集性可能同时反映遗传与环境因素,研究设计无法区分两者贡献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antidepressant responses and the phenotype of treatment-resistant depression (TRD) are believed to have a genetic basis. Genetic susceptibility between the TRD phenotype and other psychiatric disorders has also been established in previous genetic studies, but population-based cohort studies have not yet provided evidence to support these outcomes. OBJECTIVE: To estimate the TRD susceptibility and the susceptibility between TRD and other psychiatric disorders within families in a nationwide insurance cohort with extremely high coverage and comprehensive health care data. DESIGN, SETTING, AND PARTICIPANTS: This cohort study assessed data from the Taiwan national health insurance database across entire population (N = 26 554 001) between January 2003 and December 2017. Data analysis was performed from August 2021 to April 2023. TRD was defined as having experienced at least 3 distinct antidepressant treatments in the current episode, each with adequate dose and duration, based on the prescribing records. Then, we identified the first-degree relatives of individuals with TRD (n = 34 467). A 1:4 comparison group (n = 137 868) of first-degree relatives of individuals without TRD was arranged for the comparison group, matched by birth year, sex, and kinship. MAIN OUTCOMES AND MEASURES: Modified Poisson regression analyses were performed and adjusted relative risks (aRRs) and 95% CIs were calculated for the risk of TRD, the risk of other major psychiatric disorders, and different causes of mortality. RESULTS: This study included 172 335 participants (88 330 male and 84 005 female; mean [SD] age at beginning of follow-up, 22.9 [18.1] years). First-degree relatives of individuals with TRD had lower incomes, more physical comorbidities, higher suicide mortality, and increased risk of developing TRD (aRR, 9.16; 95% CI, 7.21-11.63) and higher risk of other psychiatric disorders than matched control individuals, including schizophrenia (aRR, 2.36; 95% CI, 2.10-2.65), bipolar disorder (aRR, 3.74; 95% CI, 3.39-4.13), major depressive disorder (aRR, 3.65; 95% CI, 3.44-3.87), attention-deficit/hyperactivity disorders (aRR, 2.38; 95% CI, 2.20-2.58), autism spectrum disorder (aRR, 2.26; 95% CI, 1.86-2.74), anxiety disorder (aRR, 2.71; 95% CI, 2.59-2.84), and obsessive-compulsive disorder (aRR, 3.14; 95% CI, 2.70-3.66). Sensitivity and subgroup analyses validated the robustness of the findings. CONCLUSIONS AND RELEVANCE: To our knowledge, this study is the largest and perhaps first nationwide cohort study to demonstrate TRD phenotype transmission across families and coaggregation with other major psychiatric disorders. Patients with a family history of TRD had an increased risk of suicide mortality and tendency toward antidepressant resistance; therefore, more intensive treatments for depressive symptoms might be considered earlier, rather than antidepressant monotherapy.
引用
- Cheng CM, Chen MH, Tsai SJ, et al. Susceptibility to Treatment-Resistant Depression Within Families. JAMA Psychiatry. 2024. PMID: 38568605. doi:10.1001/jamapsychiatry.2024.0378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。